Dysbiosis of skin microbiome and gut microbiome in melanoma progressionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether dysbiosis of the skin microbiome and the gut microbiome is associated with melanoma growth and progression. The researchers used the MeLiM porcine model, which spontaneously develops melanoma that can progress or regress, to study this relationship. They performed parallel analysis of cutaneous (skin) microbiota and faecal microbiota from the same animals, comparing melanoma tissue to healthy skin and comparing MeLiM piglets to control piglets. Bacterial composition was profiled using high throughput sequencing of the V4-V5 region of the 16S rRNA gene.
Who was studied?
The subjects were MeLiM piglets aged 8 to 12 weeks, a porcine model of melanoma progression and spontaneous regression. Skin swabs from melanoma tissue and healthy skin, along with faecal samples, were collected from the same individual animals. A control group of piglets without melanoma was also included for comparison of the faecal microbiome. The abstract does not specify the exact number of animals sampled.
What were the most important findings?
There was a significant difference in microbiome diversity and richness between melanoma tissue and healthy skin, and between the faecal microbiome of MeLiM piglets and control piglets. Principal Coordinate Analysis and Non-metric multidimensional scaling both showed clear dissimilarities between these different bacterial communities. Linear discriminant analysis was used to identify specific bacterial taxa distinguishing the groups, though the abstract text is cut off before naming these taxa. Overall, the findings indicate that melanoma progression is accompanied by detectable shifts in both cutaneous and gut bacterial community composition.
What are the greatest implications of this study?
The findings support the idea that skin microbiome alterations, not just gut microbiome alterations, may be relevant to the tumor microenvironment in melanoma. This suggests a potential link between local skin dysbiosis and systemic gut dysbiosis during melanoma progression, an area the authors note had not been previously investigated. Because the gut microbiome has already been shown to modulate response to melanoma immunotherapy, these results raise the possibility that skin microbiota could also influence tumor behavior or serve as an additional biomarker. This porcine model may offer a useful system for further mechanistic study of microbiome-melanoma interactions relevant to human disease.